Apricus Biosciences, Inc.
22.05.2012 16:13
---------------------------------------------------------------------------
SAN DIEGO, 2012-05-22 16:13 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that the United States ('U.S.')
Food and Drug Administration ('FDA') has granted the Company's request for Type
C regulatory guidance from the agency for MycoVa(tm), the Company's topical
treatment for onychomycosis, or nail fungus. The guidance is expected to be
received in late July 2012. The purpose of the requested guidance is to obtain
feedback from the agency regarding the suitability of MycoVa(tm)'s clinical
and
safety data to support a New Drug Approval ('NDA') in the U.S.The guidance will
come from the Division of Dermatology and Dental Products within the Office of
New Drugs in FDA's Center for Drug Evaluation & Research ('CDER'). MycoVa(tm)
is a
topically applied formulation of terbinafine hydrochloride, a well-known
medication for nail fungus, delivered with Dodecyl 2-(N, N
dimethylamino)-propionate hydrochloride (DDAIP HCl), Apricus Bio's proprietary
NexACT(r) delivery technology, which enhances absorption of drugs through the
skin and other barriers including the nail plate and nail bed. The Company
believes MycoVa(tm) clinical trials have exhibited a significant mycological
effect to eradicate the fungus and also has successfully demonstrated
non-inferiority compared to Loceryl(r), the current topical standard of care
for
onychomycosis in Europe. In addition, Apricus Bio believes the safety profile
of topical terbinafine is significantly improved and much better tolerated than
oral terbinafine, which is limited in use in some patients due to its potential
for liver toxicity.
'This FDA guidance is an integral step in the process of bringing the safe and
effective treatment benefits of MycoVa(tm) to patients suffering from mild to
moderate onychomycosis,' said Bassam Damaj, PhD, President and Chief Executive
Officer of Apricus Bio. 'Extensive clinical trial data and a robust
international patent estate firmly support the marketing potential of
MycoVa(tm)
and we look forward to receiving necessary guidance from the FDA to move the
process forward in the U.S.'
Apricus Bio was recently granted a Pre-New Drug Submission ('Pre-NDS') meeting
for MycoVa(tm) with Health Canada which is scheduled to take place on July 18,
2012, and the Company is also working with its European agents to conduct
similar meetings with various European health agencies. The Company is
currently partnered with Stellar Pharmaceuticals Inc. for the commercialization
and marketing of MycoVa(tm) in Canada following receipt of regulatory approval
by
Health Canada.
About MycoVa(tm)
In a 2009 Phase 3 clinical comparator study, MycoVa(tm) was determined to be no
less effective than Loceryl(r) in curing nail fungus. In this study, 1,029
patients with mild to moderate nail fungus were given either MycoVa(tm)
(topical
10% terbinafine hydrogen chloride formulation) or Loceryl(r) (5% amorolfine
nail
laquer) for 48 weeks. The primary endpoint was a complete cure, and the
secondary endpoints were killing the fungus and improving the appearance of the
nail. A formal reanalysis of initial study results showed no significant
difference in either primary or secondary endpoints between MycoVa(tm) and
Loceryl(r). Loceryl(r) is a registered trademark of Galderma.
MycoVa(tm) was also the subject of two Phase 3, randomized, double-blind,
vehicle
controlled, multicenter, parallel group studies to assess the efficacy, safety,
and tolerability of MycoVa(tm). A combined, post-hoc analysis of these two
Phase 3
clinical studies, completed by Apricus Bio in 2011, demonstrated statistically
significant results in mycological cure, resulting in the eradication of nail
fungus in favor of MycoVa(tm) treatment in patients that did not present with
comorbid tinea pedis (athlete's foot).
In the Company's view, MycoVa(tm) has distinct advantages over Loceryl(r) for
nail
fungus suffers. MycoVa(tm) is simple and easy to apply, which could greatly
improve patient compliance. The product is applied directly to the infected
nails, typically at bedtime, accompanied by a simple washing with soap and
water. The formulation allows significant amounts of the active ingredient to
penetrate through the nail plate to the nail bed and surrounding area where
fungus is located without significant systemic exposure. By contrast,
Loceryl(r)
requires more patient care before applying the lacquer, including filing the
affected areas of nail, including the nail surfaces, as thoroughly as possible.
The surface of the nail should then be cleansed using disposable swabs. The
nail lacquer is then applied onto the entire surface of the infected nail(s)
using reusable applicators. Before repeat application of Loceryl(r), the
affected
nails should be filed down again and wiped with a cleansing pad to remove any
residual lacquer.
About Onychomycosis
Onychomycosis is a chronic persistent fungal infection of the nail bed resulting
in thickening and discoloration of the nail, which sometimes can be accompanied
by serious pain and disability. According to the Merck Manual, the worldwide
incidence rate of onychomycosis is approximately 10%. As described by Iorizzo
and Piraccini (2007), the incidence has been increasing due to diabetes,
immunosuppression and an aging population. While occurring in approximately
2.6% of children younger than 18 years, it occurs in as much as 90% of the
elderly population (eMedicine.medscape.com). As of 2008, Thomson Reuters Pharma
had stated that the worldwide market was approximately $2.8 billion in size and
is expected to grow to approximately $2.9 billion by 2014.
About Apricus Biosciences, Inc.
Apricus Bio is a San Diego-based revenue-generating pharmaceutical company, with
commercial products and a broad pipeline across numerous therapeutic classes.
Revenues and growth are driven from the sales of the Company's commercial
products through its Apricus Pharmaceuticals USA, Inc. and NexMed (USA), Inc.
subsidiaries and through out-licensing in certain territories of its product
pipeline and NexACT(r) technology.
Apricus Bio's current NexACT(r) pipeline includes Vitaros(r), approved in
Canada for
the treatment of erectile dysfunction, as well as compounds in development from
pre-clinical through pre-registration currently focused on Sexual Dysfunction,
Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Consumer
Healthcare.
Apricus Bio currently markets Totect(r) (dexrazoxane HCl), the only drug
approved
in the US for the treatment of anthracycline extravasation. The Company also
plans to market in the U.S. or certain other countries the following products:
(a) Granisol(r) (granisetron HCI) oral solution, the only FDA-approved, oral,
ready-to-use liquid solution of granisetron, (b) Aquoral(tm), an FDA-cleared,
prescription-only spray for the treatment of Xerostomia (the medical term for
dry mouth due to a lack of saliva) and (c) NitroMist(tm) (nitroglycerin
sublingual
spray), an FDA-approved nitrate vasodilator indicated for acute relief of an
attack or acute prophylaxis of angina pectoris (chest pain) due to coronary
artery disease (narrowing of the blood vessels that supply blood to the heart).
The Company also expects to develop and/or acquire and then bring to market
additional pharmaceutical products in areas of care that will benefit patient
needs worldwide.
For further information on Apricus Bio, visit http://www.apricusbio.com, and for
information on its subsidiary please visit http://www.nexmedusa.com. You can
also receive information at http://twitter.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to further develop its products and
product candidates, to have its products and product candidates such as
MycoVa(tm)
receive patent protection and be approved by relevant regulatory authorities,
to successfully commercialize such products as Totect(r) , Granisol(r) ,
Aquoral(tm)
and NitroMist(tm) and Vitaros(r) for erectile dysfunction and NexACT(r)
product
candidates and drug delivery technology and to achieve its development,
commercialization and financial goals. Readers are cautioned not to place undue
reliance on these forward-looking statements as actual results could differ
materially from the forward-looking statements contained herein. Readers are
urged to read the risk factors set forth in the Company's most recent annual
report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other
filings made with the SEC. Copies of these reports are available from the SEC's
website or without charge from the Company.
CONTACT: Apricus Bio Investor Relations: David Pitts Argot Partners 212-600-1902
david@argotpartners.com
News Source: NASDAQ OMX
22.05.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Apricus Biosciences Granted Regulatory Guidance With FDA for MycoVa(TM) for the Treatment of Onychomycosis
| Source: EQS Group AG